ClinicalTrials.gg
CompletedNCT01405508Updated Jul 11, 2018Results posted

Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy

A Phase 3 interventional study of Brivaracetam tablets and Brivaracetam bolus in Epilepsy, sponsored by UCB Pharma. Completed at 17 sites in 4 countries. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-07-11.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
16 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Enrollment
15th of 34
105 · median 94
Started
2011
with 3 others
Phase 3
21 of 34
1 open now
Registered
18th of 34
by date
Lead sponsor
13 of 34
UCB Pharma

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 15th largest by enrollment, is one of 4 that started in 2011, is one of 21 in phase 3, and was the 18th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

This is a multicenter, open-label, 4-arm, randomized, parallel-group study to evaluate safety and tolerability of Brivaracetam Intravenous (BRV iv) as adjunctive treatment for adults with epilepsy according to an initiation or a conversion scheme, during repeated dosing (100 mg/administration twice daily for 4.5 days).

Read the detailed description

Eligible subjects will be randomized in a 1:1:1:1 ratio to the 4 treatment arms

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • N01258
  • Brivaracetam
  • Epilepsy
  • IV
  • intravenous
04

Who can participate

Ages eligible
16 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An Institutional Review Board/Independent Ethics Committee (IRB/IEC) approved written form signed and dated by the subject or by parent(s) or legal representative
  • Subjects from 16 to 70 years
  • Subjects with a body weight of >/= 40 kg
  • Female subjects without or female subjects with childbearing potential if they use a medically accepted method
  • Subject/legal representative considered as reliable and capable of adhering to the protocol
  • Subjects with well-characterized focal or generalized epilepsy or epileptic syndrome
  • Subjects with a history of partial-onset seizures whether or not secondarily generalized or primary generalized seizures
  • Subjects being uncontrolled while treated with 1 to 2 permitted concomitant antiepileptic drugs (AEDs)
  • Permitted concomitant antiepileptic drugs (AEDs) and vagus nerve stimulation (VNS) being stable and at optimal dosage for the subject from at least 1 month before Visit 1 and expected to be kept stable during the Run-In and Evaluation Periods

Exclusion criteria

Exclusion Criteria:

  • Mentally impaired subjects unable to understand the study purpose
  • History or presence of status epilepticus during 1 year preceding Visit 1 or Baseline
  • Subjects on felbamate with less than 18 months continuous exposure before Visit 1
  • Subjects currently on vigabatrin
  • Subject taking any drug with possible relevant central nervous system effects except is stable from at least 1 month before Visit 1 and expected to be kept stable during the trial
  • Subjects taking any drug that may significantly influence the metabolism of Brivaracetam (BRV) except if the dose has been kept stable at least 1 month before Visit 1, and is expected to be kept stable during the trial
  • History of cerebrovascular accident in the last 6 months
  • Subjects suffering from severe cardiovascular disease or peripheral vascular disease
  • Presence of any sign suggesting rapidly progressing brain disorder or brain tumor
  • Any clinical conditions which impair reliable participation in the study or necessitate the use of medication not allowed by protocol
  • Presence of a terminal illness
  • Presence of a serious infection
  • Subjects with a history of sever adverse hematologic reaction to any drug
  • Subjects suffering from severe disturbance of hemostasis
  • Impaired hepatic function: (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT) values of more than 3 times the upper limit of the reference range
  • Subjects having deviations from reference range values for laboratory parameters: calculated \< 50 ml / min, \< 100,000 / µL, or neutrophil cells \< 1,800 / µL
  • Clinically significant (ECG) abnormalities according to the Investigator
  • History of suicide attempt
  • In the Investigator's medical judgment, any current suicidal ideation or other serious psychiatric disorders requiring of having required hospitalization or medication
  • Known allergic reaction or intolerance to pyrrolidone derivatives and / or product
  • Known multiple drug allergies or severe drug allergy
  • Pregnant or lactating women
  • Known alcohol or drug addiction or abuse within the last 2 years
  • Subject institutionalized under judicial decision
  • Problems of venous accessibility
  • Subject taking part in another clinical / pharmacological study in the month preceding enrollment (Visit 1)
  • Investigators, coinvestigators, their spouses or children, or any study collaborators
  • Subjects previously treated with Brivaracetam (BRV)
  • Subject previously screened within this study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Placebo tablets / Brivaracetam bolus

    Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) bolus for 4.5 days. Down-Titration: * If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In * If subject discontinues during the Evaluation Period or after Day 12, the subject will receive Placebo tablets during Down-Titration: Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week

    Drug: Brivaracetam bolus · Other: Placebo

  • Experimental
    Brivaracetam (BRV) tablets / BRV bolus

    Subjects will receive Brivaracetam (BRV) tablets for one week followed by BRV bolus for 4.5 days. Down-Titration: * If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In * If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration: Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake bid for the fourth week

    Drug: Brivaracetam tablets · Drug: Brivaracetam bolus

  • Experimental
    Placebo tablets / Brivaracetam infusion

    Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) intravenous infusion for 4.5 days. Down-Titration: * If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In * If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration: Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week

    Drug: Brivaracetam infusion · Other: Placebo

  • Experimental
    Brivaracetam (BRV) tablets / BRV infusion

    Subjects will receive Brivaracetam (BRV) tablets for one week followed by Brivaracetam intravenous infusion for 4.5 days. Down-Titration: * If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In * If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration: Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week

    Drug: Brivaracetam tablets · Drug: Brivaracetam infusion

Interventions

  • 100 mg, intake twice daily (BID) for 7 days during Run-In Period

  • DrugBrivaracetam bolus

    10 mL (= 100 mg) of Brivaracetam administered intravenously over 2 minutes twice daily (BID) during Evaluation Period

  • 10 mL (= 100 mg) of Brivaracetam diluted in 90 mL 0.9 % isotonic saline sterile solution for intravenous administration infused over 15 minutes twice daily (BID) during Evaluation Period

  • OtherPlacebo

    100 mg twice daily (BID) for 7 days during Run-In Period

06

What researchers measure

Primary outcomes

  1. Number of Subjects With at Least One Treatment-emergent Adverse Event During the Study (Maximum 40 Days)

    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: 40 days

Secondary outcomes

  1. Number of Subjects Who Withdrew Due to a Treatment-emergent Adverse Event During the Study (Maximum 40 Days)

    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: 40 days

  2. Number of Subjects With at Least One Injection-related Treatment-emergent Adverse Event (TEAE) During the Evaluation Period.

    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: 4.5-day Evaluation Period

07

Results

Posted Apr 13, 2016

Participant flow

This study started to recruit patients in August 2011 and concluded in July 2012. 105 subjects were randomized to 4 different treatment groups.

Participant flow — Overall Study
MilestonePlacebo Tablets / Brivaracetam BolusPlacebo Tablets / Brivaracetam InfusionBrivaracetam (BRV) Tablets / BRV BolusBrivaracetam (BRV) Tablets / BRV Infusion
Started26262726
Completed25252726
Not completed1100
Withdrew: Ae, non-serious non-fatal1100

Outcome measures

PrimaryNumber of Subjects With at Least One Treatment-emergent Adverse Event During the Study (Maximum 40 Days)

An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

Time frame:
40 days
Reported as:
Number · Participants
Number of Subjects With at Least One Treatment-emergent Adverse Event During the Study (Maximum 40 Days)
ParticipantsPlacebo Tablets / Brivaracetam BolusPlacebo Tablets / Brivaracetam InfusionBrivaracetam (BRV) Tablets / BRV BolusBrivaracetam (BRV) Tablets / BRV Infusion
Number of Subjects With at Least One Treatment-emergent Adverse Event During the Study (Maximum 40 Days)20192120
SecondaryNumber of Subjects Who Withdrew Due to a Treatment-emergent Adverse Event During the Study (Maximum 40 Days)

An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

Time frame:
40 days
Reported as:
Number · Participants
Number of Subjects Who Withdrew Due to a Treatment-emergent Adverse Event During the Study (Maximum 40 Days)
ParticipantsPlacebo Tablets / Brivaracetam BolusPlacebo Tablets / Brivaracetam InfusionBrivaracetam (BRV) Tablets / BRV BolusBrivaracetam (BRV) Tablets / BRV Infusion
Number of Subjects Who Withdrew Due to a Treatment-emergent Adverse Event During the Study (Maximum 40 Days)1100
SecondaryNumber of Subjects With at Least One Injection-related Treatment-emergent Adverse Event (TEAE) During the Evaluation Period.

An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

Time frame:
4.5-day Evaluation Period
Reported as:
Number · Participants
Number of Subjects With at Least One Injection-related Treatment-emergent Adverse Event (TEAE) During the Evaluation Period.
ParticipantsPlacebo Tablets / Brivaracetam BolusPlacebo Tablets / Brivaracetam InfusionBrivaracetam (BRV) Tablets / BRV BolusBrivaracetam (BRV) Tablets / BRV Infusion
Number of Subjects With at Least One Injection-related Treatment-emergent Adverse Event (TEAE) During the Evaluation Period.1343

Adverse events

Collected over Adverse Events were collected from Baseline over Run-In (Day 1) and Evaluation Period (Day 8 to Day 12) to the Safety Visit or Early Discontinuation Visit (up to 54 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Tablets / Brivaracetam Bolus—0/26 (0%)17/26 (65.4%)
Placebo Tablets / Brivaracetam Infusion—0/26 (0%)15/26 (57.7%)
Brivaracetam (BRV) Tablets / BRV Bolus—0/27 (0%)15/27 (55.6%)
Brivaracetam (BRV) Tablets / BRV Infusion—0/26 (0%)14/26 (53.8%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlacebo Tablets / Brivaracetam BolusPlacebo Tablets / Brivaracetam InfusionBrivaracetam (BRV) Tablets / BRV BolusBrivaracetam (BRV) Tablets / BRV Infusion
SomnolenceNervous system disorders8/267/267/279/26
DizzinessNervous system disorders4/264/263/274/26
Infusion site painGeneral disorders0/263/262/270/26
RashSkin and subcutaneous tissue disorders3/261/260/270/26
FatigueGeneral disorders1/262/263/270/26
Postural orthostatic tachycardia syndromeCardiac disorders2/260/261/270/26
HeadacheNervous system disorders2/261/262/272/26
DysgeusiaNervous system disorders2/260/262/270/26
CoughRespiratory, thoracic and mediastinal disorders0/262/260/270/26
VertigoEar and labyrinth disorders1/261/262/271/26

Baseline characteristics

Baseline Characetristics refer to the Safety Population consisting of all subjects who took at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)Placebo Tablets / Brivaracetam BolusPlacebo Tablets / Brivaracetam InfusionBrivaracetam (BRV) Tablets / BRV BolusBrivaracetam (BRV) Tablets / BRV InfusionTotal Title
<=18 years00000
Between 18 and 65 years26252725103
>=65 years01012
Age, Continuous
Age, Continuous(years)Placebo Tablets / Brivaracetam BolusPlacebo Tablets / Brivaracetam InfusionBrivaracetam (BRV) Tablets / BRV BolusBrivaracetam (BRV) Tablets / BRV InfusionTotal Title
Mean40.6 ± 12.239.5 ± 14.442.0 ± 9.244.4 ± 12.641.6 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Tablets / Brivaracetam BolusPlacebo Tablets / Brivaracetam InfusionBrivaracetam (BRV) Tablets / BRV BolusBrivaracetam (BRV) Tablets / BRV InfusionTotal Title
Female1210171756
Male141610949
08

Study locations

17 sites
  • 001
    Phoenix, Arizona, United States
  • 775
    Little Rock, Arkansas, United States
  • 780
    Lexington, Kentucky, United States
  • 008
    Bethesda, Maryland, United States
  • 778
    Columbus, Ohio, United States
  • 776
    Nashville, Tennessee, United States
  • 777
    Dallas, Texas, United States
  • 036
    Charlottesville, Virginia, United States
  • 917
    Brno, Czechia
  • 915
    Hradec Kralove, Czechia
  • 916
    Kromeriz, Czechia
  • 913
    Ostrava Poruba, Czechia
  • 332
    Bielefeld, Germany
  • 903
    Bonn, Germany
  • 795
    Katowice, Poland
  • 479
    Poznan, Poland
  • 794
    Warszawa, Poland
09

References and documents

Publications

  • Toledo M, Brandt C, Quarato PP, Schulz AL, Cleveland JM, Wagener G, Klein P. Long-term safety, efficacy, and quality of life during adjunctive brivaracetam treatment in patients with uncontrolled epilepsy: An open-label follow-up trial. Epilepsy Behav. 2021 May;118:107897. doi: 10.1016/j.yebeh.2021.107897. Epub 2021 Mar 27. PubMed 33780735 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 3 years 9 months after primary completion. A results delay was requested in Jun 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2011
First posted
Jul 29, 2011
Start
Aug 2011
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results delay requested
Jun 3, 2013
Results first posted
Apr 13, 2016
Last update
Jul 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01405508
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Jul 29, 2011
Start date
Aug 2011
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
Apr 13, 2016
Last update
Jul 11, 2018

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion